| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282182 | Clinical Gastroenterology and Hepatology | 2013 | 11 Pages |
Abstract
The addition of boceprevir after 4 weeks of lead-in therapy with PEG2a/R caused significantly higher rates of SVR in previously treated patients with chronic HCV genotype-1 infection, compared with patients given only PEG2a/R. ClinicalTrials.gov Identifier: NCT00845065.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Steven L. Flamm, Eric Lawitz, Ira Jacobson, Marc Bourlière, Christophe Hezode, John M. Vierling, Bruce R. Bacon, Claus Niederau, Morris Sherman, Venkata Goteti, Heather L. Sings, Richard O. Barnard, John A. Howe, Lisa D. Pedicone, Margaret H. Burroughs,